Merck & Company (MRK)

$123.93 +0.11 (0.09%)
Market Cap 303.45B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 13.59
Forward PE 23.70
Profit Margin 28.08%
Debt to Equity Ratio 0.77
Volume 8,460,440
Avg Vol 13,510,682
Day's Range N/A - N/A
Shares Out 2.48B
Stochastic %K 95%
Beta 0.28
Analysts Strong Sell
Price Target $126.76

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
macrossluvsrobotech
macrossluvsrobotech Feb. 24 at 8:38 PM
$IBRX No need for Chemo, just super charge your InterLeukins, ie, your own immune system to go and target cancer cells. Amazing. This will not stop here. Long. Revenues clearly show it's working and demand is high. Long. But ANY volatility dips. $GILD $BIB $JNJ $MRK
0 · Reply
Sunny3999
Sunny3999 Feb. 24 at 8:00 PM
$PMN accumulation at its best $ABBV $BMY $MRK $PMN $SNY
0 · Reply
wallstgirl
wallstgirl Feb. 24 at 5:59 PM
$MRK
0 · Reply
taxplanr
taxplanr Feb. 24 at 5:58 PM
Ivermectin Fenbendazole and Mebendazole in Saudi Arabia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-07d?utm_source=post-email-title&publication_id=1385328&post_id=189043070&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Rm586
Rm586 Feb. 24 at 5:53 PM
$IBRX I’ll say it again. Keytruda is a 30b a year oncology drug. $MRK is trading at 17x forward revs. They have 2.4 billion shares. Do the math. 🚀
1 · Reply
chrisdacs
chrisdacs Feb. 24 at 4:30 PM
$MRK remember kids. There’s no money in curing cancer only treating it.
0 · Reply
prismmarketview
prismmarketview Feb. 24 at 2:45 PM
Cancer immunotherapy—from checkpoint inhibitors and CAR‑T cells to bispecific antibodies and personalized vaccines—is rapidly transforming oncology outcomes and propelling a market expected to surpass 250 billion dollars over the next decade as biotech innovation accelerates. Merck & Co., Inc. (NYSE: $MRK) Bristol Myers Squibb (NYSE: $BMY) https://prismmarketview.com/cancer-immunotherapy-breakthroughs-are-transforming-oncology-and-driving-biotech-growth/
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 2:01 PM
$JAZZ $LEXX $MRK $TEVA
0 · Reply
Rm586
Rm586 Feb. 24 at 1:22 PM
IBRX $MRK keytruda is over 30b a year. Accounts for half their revenue. They trade at 17x earnings. They have 2.5 billion shares… do the math. Know what you own. Forgot to mention, we have +40% short here. 🚀
1 · Reply
cb5000calls
cb5000calls Feb. 24 at 1:28 AM
$SLS @Love_To_Learn are we waiting on $MRK $ABBV or $PFE to light the fuse here and trigger the #SuperNova to triple digit PT. We all know that all three desperately need to make a move soon or their patents are in deep trouble. GPS is the next paradigm shift in cancer treatement, the WT1 market is too big for SLS to handle, buyout is the only option.
2 · Reply
Latest News on MRK
Merck to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 6:45 AM EST - 12 hours ago

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 1 day ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRNA PFE

Merck creates separate oncology arm ahead of Keytruda patent loss

Feb 23, 2026, 9:11 AM EST - 1 day ago

Merck creates separate oncology arm ahead of Keytruda patent loss

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Feb 23, 2026, 7:38 AM EST - 1 day ago

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Feb 23, 2026, 6:45 AM EST - 1 day ago

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Feb 23, 2026, 6:22 AM EST - 1 day ago

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

Feb 23, 2026, 6:00 AM EST - 1 day ago

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

Feb 23, 2026, 5:12 AM EST - 1 day ago

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

AMGN CBSH COF DHR LEN MSFT PH

Merck: Why Investors Should Remain Bullish Despite Patent Risks

Feb 22, 2026, 8:00 AM EST - 2 days ago

Merck: Why Investors Should Remain Bullish Despite Patent Risks

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Feb 19, 2026, 5:15 AM EST - 5 days ago

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery

Feb 18, 2026, 1:05 PM EST - 6 days ago

Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Feb 18, 2026, 6:45 AM EST - 6 days ago

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

Feb 16, 2026, 10:58 AM EST - 8 days ago

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

AMD GOOG LLY ORCL ZTS

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction

Feb 12, 2026, 9:00 AM EST - 12 days ago

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 12 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Feb 12, 2026, 6:45 AM EST - 12 days ago

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Feb 11, 2026, 6:45 AM EST - 13 days ago

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

Feb 10, 2026, 4:35 AM EST - 14 days ago

Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

Merck: The Spike Doesn't Make It Overvalued

Feb 9, 2026, 1:32 PM EST - 15 days ago

Merck: The Spike Doesn't Make It Overvalued

Merck: A Buy For 2026, But The Clock Is Still Ticking

Feb 9, 2026, 9:55 AM EST - 15 days ago

Merck: A Buy For 2026, But The Clock Is Still Ticking

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

Feb 8, 2026, 10:28 PM EST - 15 days ago

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum

Feb 8, 2026, 9:56 PM EST - 15 days ago

Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

Feb 4, 2026, 8:15 AM EST - 20 days ago

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

MRNA

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 1:30 PM EST - 21 days ago

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 21 days ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

PFE

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Feb 3, 2026, 11:06 AM EST - 21 days ago

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Feb 3, 2026, 7:14 AM EST - 21 days ago

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Feb 3, 2026, 6:55 AM EST - 21 days ago

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Merck Earnings Top Estimates. Why the Stock Is Falling.

Feb 3, 2026, 6:48 AM EST - 21 days ago

Merck Earnings Top Estimates. Why the Stock Is Falling.

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Feb 3, 2026, 6:38 AM EST - 21 days ago

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Merck forecasts 2026 sales below estimates on patent losses

Feb 3, 2026, 6:34 AM EST - 21 days ago

Merck forecasts 2026 sales below estimates on patent losses

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Feb 3, 2026, 6:31 AM EST - 21 days ago

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Feb 3, 2026, 6:30 AM EST - 21 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

5 Stocks That Could Outperform Even in a Pullback

Jan 30, 2026, 1:09 PM EST - 25 days ago

5 Stocks That Could Outperform Even in a Pullback

HON MSFT PG

What's Fueling The Rally In Merck Stock?

Jan 28, 2026, 11:10 AM EST - 27 days ago

What's Fueling The Rally In Merck Stock?

Merck Announces Second-Quarter 2026 Dividend

Jan 27, 2026, 3:07 PM EST - 4 weeks ago

Merck Announces Second-Quarter 2026 Dividend

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

Jan 26, 2026, 10:30 PM EST - 4 weeks ago

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

A ADBE AXP B C CBOE CHKP

Overlooked Stock: RVMD Sells After MRK Turns Away

Jan 26, 2026, 4:30 PM EST - 4 weeks ago

Overlooked Stock: RVMD Sells After MRK Turns Away

RVMD

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

Jan 26, 2026, 6:01 AM EST - 4 weeks ago

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

RVMD

Merck no longer in talks to buy Revolution Medicines, WSJ reports

Jan 25, 2026, 3:27 PM EST - 4 weeks ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

RVMD

Merck No Longer in Talks to Buy Revolution Medicines

Jan 25, 2026, 2:30 PM EST - 4 weeks ago

Merck No Longer in Talks to Buy Revolution Medicines

RVMD

Top 10 Dividend Stocks For Uncertain Times

Jan 22, 2026, 5:00 AM EST - 4 weeks ago

Top 10 Dividend Stocks For Uncertain Times

BMY CDP DRH HST LNC PINE PSX

Merck partners with global health coalition to develop affordable Ebola vaccine

Jan 21, 2026, 11:01 AM EST - 4 weeks ago

Merck partners with global health coalition to develop affordable Ebola vaccine

Moderna, Merck Report Positive Results From Cancer-Vaccine Study

Jan 20, 2026, 6:58 AM EST - 5 weeks ago

Moderna, Merck Report Positive Results From Cancer-Vaccine Study

MRNA

Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

Jan 20, 2026, 6:25 AM EST - 5 weeks ago

Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

MRNA

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Jan 20, 2026, 6:00 AM EST - 5 weeks ago

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

MRNA

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Jan 16, 2026, 8:40 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS GSK

Is Merck Stock A Trap At $110?

Jan 15, 2026, 9:10 AM EST - 5 weeks ago

Is Merck Stock A Trap At $110?

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 10:25 PM EST - 6 weeks ago

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

Jan 12, 2026, 8:01 PM EST - 6 weeks ago

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

macrossluvsrobotech
macrossluvsrobotech Feb. 24 at 8:38 PM
$IBRX No need for Chemo, just super charge your InterLeukins, ie, your own immune system to go and target cancer cells. Amazing. This will not stop here. Long. Revenues clearly show it's working and demand is high. Long. But ANY volatility dips. $GILD $BIB $JNJ $MRK
0 · Reply
Sunny3999
Sunny3999 Feb. 24 at 8:00 PM
$PMN accumulation at its best $ABBV $BMY $MRK $PMN $SNY
0 · Reply
wallstgirl
wallstgirl Feb. 24 at 5:59 PM
$MRK
0 · Reply
taxplanr
taxplanr Feb. 24 at 5:58 PM
Ivermectin Fenbendazole and Mebendazole in Saudi Arabia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-07d?utm_source=post-email-title&publication_id=1385328&post_id=189043070&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Rm586
Rm586 Feb. 24 at 5:53 PM
$IBRX I’ll say it again. Keytruda is a 30b a year oncology drug. $MRK is trading at 17x forward revs. They have 2.4 billion shares. Do the math. 🚀
1 · Reply
chrisdacs
chrisdacs Feb. 24 at 4:30 PM
$MRK remember kids. There’s no money in curing cancer only treating it.
0 · Reply
prismmarketview
prismmarketview Feb. 24 at 2:45 PM
Cancer immunotherapy—from checkpoint inhibitors and CAR‑T cells to bispecific antibodies and personalized vaccines—is rapidly transforming oncology outcomes and propelling a market expected to surpass 250 billion dollars over the next decade as biotech innovation accelerates. Merck & Co., Inc. (NYSE: $MRK) Bristol Myers Squibb (NYSE: $BMY) https://prismmarketview.com/cancer-immunotherapy-breakthroughs-are-transforming-oncology-and-driving-biotech-growth/
0 · Reply
Makingmillions192
Makingmillions192 Feb. 24 at 2:01 PM
$JAZZ $LEXX $MRK $TEVA
0 · Reply
Rm586
Rm586 Feb. 24 at 1:22 PM
IBRX $MRK keytruda is over 30b a year. Accounts for half their revenue. They trade at 17x earnings. They have 2.5 billion shares… do the math. Know what you own. Forgot to mention, we have +40% short here. 🚀
1 · Reply
cb5000calls
cb5000calls Feb. 24 at 1:28 AM
$SLS @Love_To_Learn are we waiting on $MRK $ABBV or $PFE to light the fuse here and trigger the #SuperNova to triple digit PT. We all know that all three desperately need to make a move soon or their patents are in deep trouble. GPS is the next paradigm shift in cancer treatement, the WT1 market is too big for SLS to handle, buyout is the only option.
2 · Reply
NYCDallas
NYCDallas Feb. 23 at 10:56 PM
$MRK does mrk and sls have a chance
0 · Reply
sasanalyst
sasanalyst Feb. 23 at 10:34 PM
$ERAS This will be a juicy acquisition for Merck $MRK as now they split their Oncology business. Looks like they want to do multiple small acquisitions after opting out of the RAS pioneer $RVMD
1 · Reply
T_L808
T_L808 Feb. 23 at 9:30 PM
$MRK well...
0 · Reply
jogabonito84
jogabonito84 Feb. 23 at 7:56 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
0 · Reply
ajbski
ajbski Feb. 23 at 7:00 PM
$NVAX 🤔 “Girding against Keytruda cliff, Merck splits oncology into standalone business unit”. Feb 23, 2026 #Biotech $MRK https://www.fiercepharma.com/pharma/girding-against-keytruda-cliff-merck-splits-oncology-standalone-business-unit?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FiercePharma&oly_enc_id=9341H3878112J6N
0 · Reply
RealImbackbears
RealImbackbears Feb. 23 at 4:14 PM
$SLS $MRK just made a 52 week high , Keytruda making boat loads of money and will be used with SLS GPS with many different cancer treatments for immunotherapy
0 · Reply
harmongreg
harmongreg Feb. 23 at 3:49 PM
Dragonfly Capital - 4 Trade Ideas for Merck: Bonus Idea $MRK https://dragonflycap.com/4-trade-ideas-for-merck-bonus-idea-9/
0 · Reply
Ventureville
Ventureville Feb. 23 at 3:39 PM
$BIOV.CSE $BVAXF is sitting where biotech reversals start. While $LLY $NVO $MRK are priced like winners, small caps like BIOV can rerate hard when data hits. DPX platform quietly advancing across multiple cancers. Bears see red. Bulls see setup. $LLY $NVO $MRK
0 · Reply
Amit18
Amit18 Feb. 23 at 3:32 PM
$IBRX $MRK is doing everything to stay relevant in cancer market
1 · Reply
TrustButVerifi
TrustButVerifi Feb. 23 at 3:26 PM
$VKTX BP alert! @ $NVO $MRK $ABBV $BMY Fk your next generation and look for this generation as Lilly is gonna eat all your lunch if U dont wake the fk up!
0 · Reply
Indyson
Indyson Feb. 23 at 3:13 PM
$SLS not to state the obvious but this $MRK news is clearly affecting us. Markets thinking keytrdua and gps could be a golden match for cancer patients
0 · Reply
taxplanr
taxplanr Feb. 23 at 3:05 PM
Lung Tumors shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-504?utm_source=post-email-title&publication_id=1385328&post_id=188711263&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply